Dortmund, June 19, 2018 – Following the seed financing round in 2016, UGISense AG has again been able to successfully complete a funding round.
In addition to all founding investors (experienced business angels in the field of biotechnology and the Lead Discovery Center Dortmund), SeedCapital II KG from Dortmund as well as the experienced business angel Dr. Uwe Jacob (Westend-Innovation), and healthcare specialist Samuel Stursberg could be convinced of the potential of UGISense AG for this funding round.
After the investment has been completed, the headquarters of the company will be transferred from Munich to Dortmund.
The capital enables UGISense to fuel the development and expansion of their proprietary antisense technology (Ugimers™) at the new site. The main goal is to document the broad applicability of the Ugimers™ in different cooperation projects with LDC, but also with partners from the industry and academia and to develop compounds for the corresponding targets. Current projects include areas such as oncology, metabolic diseases as well as muscular dystrophies.
We are very happy that, in addition to all of the seed investors, we have also been able to fill new investors with enthusiasm for our technology”, say Dr. Birgit Werner and Dr. Thomas Lindhorst, the members of the executive board. “The fresh capital enables us to further distinguish the superiority of the ugimer technology compared to other antisense technologies and to prove the same by means of an extensive pool of data.
T.: +49 231 9742 7063
T.: +49 231 1833 34201
Lead Discovery Center
T.: +49 231 9742 7000
About UGISense AG
UGISense AG is a biotech company dedicated to developing new and innovative antisense drugs in collaboration with partners from the industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the UgimersTM. The company, which was first established in 2016, is being financed by private investors, the Lead Discovery Center Dortmund GmbH and the Seed Capital II GmbH and has been accredited by the Federal Office of Economics and Export Control (BAFA) (within the scope of their Venture Capital Grants program).
>> for more details please go to www.ugisense.com
UgimersTM are short oligonucleotide sequences capable of interacting with single-stranded DNA or RNA by forming a double strand. Thanks to said double-strand formation, disease-relevant proteins will be specifically prevented from forming altogether or will be reduced to only a modified stage. This makes it possible to therapeutically influence the development of diseases at a very early stage of intervention. Structurally, UgimersTM are derived from peptide nucleic acids (PNAs) to which important pharmacological functions have been added by way of chemical modifications.
About SeedCapital II
The SeedCapital Dortmund II GmbH & Co. KG participates in young, innovative companies in the Dortmund region. Our group of partners comprises the Sparkasse Dortmund and the NRW.BANK as well as private investors. Together with our financing partners, we are able to provide a participation capital in a seven-digit range. Our cooperation partners especially include the locally based competence centres, such as the Technologiezentrum Dortmund, the BioMedizinZentrum, the MST.factory as well as the Centre of Production Technology (ZfP Dortmund).
The Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need.
The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that reach initial proof-of-concept in animals. In close collaboration with high- profile partners from academia and industry, the LDC is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential.
The LDC sustains a preferred partnership with the Max Planck Society and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson Innovation, Merck KGaA, Qurient, Roche, Sotio and various VCs as well as leading translational drug discovery centers around the globe.
>> for more details please go to www.lead-discovery.de